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Abstract
 Submacular haemorrhage is not an unusual cause of acuteIntroduction:
central vision loss, particularly in older people. It may be caused by a number of
conditions, most common of which is exudative age-related madular
degeneration. In patients affected by this type of macular degeneration,
choroidal neovascularization extends into the subretinal space, producing
substantial bleeding in approximately 17% of cases, resulting in large
haemorrhages in the subretinal space that detach the neurosensory retina from
the supporting retinal pigment epithelial (RPE) layer. This leads to substantial
vision loss because of a relatively fast process of extensive photoreceptor
atrophy in the overlying neuroretina and formation of macular scars
We describe a patient with submacular haemorrhageCase presentation: 
secondary to exudative age-related macular degeneration, treated with
intravitreal injection of dobesilate. Two months later, visual acuity in the treated
eye reached 0.50 with a significant improvement of the distortion and an
anatomical resolution of the haemorrhage, as confirmed by optical coherence
tomography.
 Submacular haemorrhage secondary to exudative age-relatedConclusions:
macular degeneration can be successfully treated with intravitreal dobesilate.
To our knowledge, this is the first case reporting a resolution of submacular
haemorrhage after a single dobesilate injection.
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Case description
A 75 year-old Caucasian man with a history of exudative age- 
related macular degeneration (AMD) in both eyes developed a sudden 
vision decrease in the right eye. The best corrected visual acuity 
(BCVA) on presentation was 0.05. Fundus examination showed a 
recent medium-sized submacular haemorrhage (SMH) (Figure 1A), 
and spectral-domain optical coherence tomography (SD-OCT) 
depicted a remarkable anomalous architecture of the retina and 
serious disturbances under the retinal pigment epithelium (RPE) 
without significant accumulation of intraretinal fluid (Figure 1D). The 
haemorrhage also seemed to have resulted in RPE detachment at some 
points (Figure 1D, asterisk). Treatment with dobesilate was recom-
mended. After approval of our Institution Ethical Committee, the 
patient signed an informed consent form, which included a com-
prehensive description of dobesilate and the proposed procedure. 
Using a standard protocol, the patient received an intravitreal solu-
tion of dobesilate (150 μl) in his right eye under sterile conditions, 
following the International Guidelines for intravitreal injections1. 
Dobesilate was administered as a 12.5% solution of diethylam-
monium 2.5-dihydroxybenzenesulfonate (etamsylate; Dicynone® 
Sanofi-Aventis, Paris, France). No ocular side effects were observed 
upon the administration of dobesilate or during the following days. 
Over two months follow-up the haemorrhage signs gradually disap-
peared (Figure 1B,C), and the SD-OCT scans showed a progressive 
normalization of the retinal architecture with the disappearance of 
the RPE detachment (Figure 1E,F). At the end of this period of two 
months, the patient’s BCVA had reached a value of 0.50.
Discussion
Patients with exudative AMD and SMH on initial presentation have 
more than a 50% chance of developing recurrent submacular bleeding 
within the first subsequent three years2. Retinal diseases character-
ized by an excess of vessel proliferation are sometimes treated with 
antibodies that inhibit vascular endothelial growth factor (VEGF). 
Recently, anti-VEGF antibodies have been also proposed for the 
management of SMH3,4. However, this therapy needs repeated 
injections in some patients and takes several months to clear SMH5. 
In addition, SMH may occur following the injection of intravitreal 
anti-VEGF agents6,7. As subretinal haemorrhages are, so far, 
inadequately addressed with the use of the current anti-angiogenic 
therapies, many different treatments have been used to physically 
remove or displace them, with inconclusive results8. Thus, safe and 
efficient therapy for SMH is needed. Here we present a patient with 
SMH secondary to exudative AMD who was successfully treated 
with a single intravitreal dobesilate injection, a synthetic inhibitor 
of fibroblast growth factor.
Using a murine model of subretinal haemorrhage it has been shown 
that, like other central nervous system locations such as the cerebral 
cortex, inactive microglia, which reside in the inner retina under 
quiescent conditions, acquire the reactive phenotype and rapidly 
migrate to the site of the haemorrhage8. Once there, microglia par-
ticipate in the phagocytosis of blood products and promote inflam-
mation at the injury site, together with leukocytes and monocytes 
of the extravasated blood, by secreting cytokines, chemokines and 
other immunomolecules. In these studies it was also shown that 
inhibition of microglial activation reduced microglial infiltration and 
photoreceptor cell loss caused by SMH8.
Microglial cells are activated by fibroblast growth factor (FGF) 
synthesized by astrocytes in the case of the central nervous sys-
tem9. In the case of hemorrhages, extravasated blood cells like 
monocyte-derived macrophages also synthesize FGF10, which also 
acts as chemoattractant of microglial cells. Furthermore, micro-
glia also synthesize FGF and other cytokines, once they have been 
activated. Since activated microglia also expresses FGF receptors 
Figure 1. Sequence of fundus photographs (A–C) and spectral-domain optical coherence tomography (SD-OCT) scans (D–F) of 
a patient with a moderate-sized submacular haemorrhage at baseline (A,D), and at one (B,E) and two months (C,F) after a single 
intravitreal injection of dobesilate. The asterisk in D indicates retinal pigment epithelium (RPE) detachment.
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explain the differences in outcome, since the intestinal flora and rel-
ative instability of dobesilate above pH 5 may significantly hamper 
the ability of the inhibitor to reach adequate concentrations in the 
retina27. FGF is involved in the homeostasis of the tissues of meso-
dermal and neuroectodermal origin. A detailed discussion about the 
apparent paradox that constitutes that the administration of a FGF 
inhibitor does not cause considerable distortion in those tissues has 
been carried out in previous articles27.
VEGF is a protein that enhances the permeability of blood vessels 
(actually, it was also isolated under the name of vascular permeabil-
ity factor). It is also, apparently, a paradox that the treatments with 
antibodies against VEGF had not shown significant therapeutic 
effects in the treatment of SMH. To shed some light on this appar-
ent contradiction one has probably to take into account the serious 
drawbacks of depleting VEGF for a long time, since it is a key 
component in the homeostasis of the retina. The clearance of those 
antibodies from the vitreous is about 10 days, although some believe 
it to be as long as 2.5 months32–34. In contrast, inhibition of FGF is 
not accompanied by a prolonged presence of dobesilate at the eye, 
as it readily decomposes at physiological pH24. We have also shown 
that dobesilate can also be used to suppress VEGF-induced angio-
genesis, as expected from the necessary synergism between VEGF 
and FGF for promoting angiogenesis35.
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(FGFRs), an autocrine loop could readily develop in the case of 
important lesions, which could sustain the appearance of chronic 
inflammation. In addition, recently published studies, point to the 
fundamental importance of activated microglia in re-shaping the 
vasculature during pathological insults9,11–16. This additional source 
of FGF may greatly contribute to the development and worsening 
of AMD.
FGF was the first inducer of vasculogenesis and proliferation of 
endothelial cells to be isolated17. Later on, it was shown that it is 
a broad-spectrum mitogen18 and, recently, that FGF should be envi-
sioned rather as an inflammation-triggering and -sustaining protein 
than as mere mitogen for mesoderm-derived cells19,20. These inflam-
matory activities are probably an important contributor to the seque-
lae of the brain and retinal haemorrhages, including development 
and worsening of AMD. FGF may further contribute to aggravate 
this scenario by directly promoting vascular permeability when it 
participates in neovessel formation17,21,22. We have shown that neo-
vascular growth induced by FGF and the accompanying bleeding 
can be suppressed with inhibitors of FGF23. Consequently, it seems 
that inhibition of FGF could be an appropriate treatment to prevent 
retinal injuries in the aftermath of haemorrhages.
We have spent important efforts in the development of synthetic 
inhibitors of FGF. These studies led to the identification of a family of 
small-size chemical inhibitors, structurally similar to gentisic acid, 
the first member of the group that was identified. The most active of 
the family was a compound known in pharmacology as dobesilate, 
the active principle of Doxium, a drug that has been orally admin-
istered for more than 35 years for the treatment of diabetic retin-
opathy with a good safety profile, but inconclusive outcomes25,26. 
Contrarily, we have obtained clear positive results in different reti-
nal pathologies27–31 by administering, off-label, dobesilate through 
intraocular injection.
Our results may seem in contradiction with those of Haritoglou 
et al.26, who carried out an accurate statistical study to assess the 
real clinical benefits of calcium dobesilate in the treatment of dia-
betic retinopathy. They concluded that the oral administration of 
dobesilate did not show statistically significant clinical benefits for 
treating this disease. Perhaps, as we discussed in detail in previous 
articles, the different administration procedures employed in the 
Haritoglou et al. study and in our treatments, respectively, may 
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In my opinion the manuscript is well written and describes the effects of intravitreal dobesilate in the
resolution of submacular haemmorrhage due to exudative AMD.
I think the authors could describe the findings of the angiogram and ICG and how they ruled out other
causes of SMH as polipoidal or RAP. As we know, polipoidal is always a diagnostic hypothesis that must
be thought when a patient has SMH.
Another point to be discussed is if the patient developed a new subretinal fluid and the possibility of a new
dobesilate administration in refractory cases. Also something not clear is that the patient was or wasn't
already submitted to intravitreal anti-VEGF injections before the dobesilate administration.
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it is of an acceptable scientific standard.
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